Wesbanco Bank Inc. boosted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 26.7% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 24,785 shares of the biopharmaceutical company's stock after acquiring an additional 5,228 shares during the period. Wesbanco Bank Inc.'s holdings in Gilead Sciences were worth $2,748,000 as of its most recent SEC filing.
Other hedge funds also recently bought and sold shares of the company. Smallwood Wealth Investment Management LLC purchased a new position in Gilead Sciences in the 1st quarter worth approximately $25,000. Activest Wealth Management grew its stake in Gilead Sciences by 2,837.5% in the 1st quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company's stock worth $26,000 after buying an additional 227 shares in the last quarter. Goodman Advisory Group LLC purchased a new position in Gilead Sciences in the 1st quarter worth approximately $29,000. Colonial Trust Advisors grew its stake in Gilead Sciences by 304.3% in the 1st quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company's stock worth $32,000 after buying an additional 213 shares in the last quarter. Finally, Core Alternative Capital grew its stake in Gilead Sciences by 370.8% in the 1st quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company's stock worth $34,000 after buying an additional 241 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company's stock.
Analysts Set New Price Targets
A number of equities analysts have commented on GILD shares. Royal Bank Of Canada boosted their price target on shares of Gilead Sciences from $96.00 to $98.00 and gave the stock a "sector perform" rating in a research note on Friday, August 8th. Dbs Bank raised shares of Gilead Sciences to a "moderate buy" rating in a research note on Friday, September 5th. Needham & Company LLC raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price objective for the company in a research note on Friday, July 25th. UBS Group upped their price objective on shares of Gilead Sciences from $108.00 to $112.00 and gave the company a "neutral" rating in a research note on Friday, August 8th. Finally, Daiwa Capital Markets raised shares of Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 price objective for the company in a research note on Tuesday, August 19th. Three analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have given a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $115.39.
Read Our Latest Research Report on GILD
Gilead Sciences Stock Down 2.8%
NASDAQ:GILD opened at $114.55 on Monday. The firm's 50-day moving average price is $114.04 and its 200-day moving average price is $110.08. The company has a market capitalization of $142.13 billion, a PE ratio of 22.82, a P/E/G ratio of 0.78 and a beta of 0.36. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. Gilead Sciences, Inc. has a 1-year low of $81.57 and a 1-year high of $121.83.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, beating the consensus estimate of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The company had revenue of $7.08 billion for the quarter, compared to the consensus estimate of $6.95 billion. During the same period in the prior year, the firm posted $2.01 EPS. Gilead Sciences's revenue for the quarter was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, equities analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.
Gilead Sciences Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Monday, September 29th. Stockholders of record on Monday, September 15th will be issued a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date of this dividend is Monday, September 15th. Gilead Sciences's dividend payout ratio (DPR) is presently 62.95%.
Insider Buying and Selling at Gilead Sciences
In other news, Director Jeffrey Bluestone sold 5,000 shares of the stock in a transaction that occurred on Monday, July 14th. The shares were sold at an average price of $109.74, for a total value of $548,700.00. Following the transaction, the director owned 8,920 shares in the company, valued at $978,880.80. This represents a 35.92% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Johanna Mercier sold 28,000 shares of the stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $118.53, for a total transaction of $3,318,840.00. Following the completion of the transaction, the insider owned 114,168 shares in the company, valued at $13,532,333.04. This trade represents a 19.70% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 76,500 shares of company stock worth $8,765,395 over the last quarter. Company insiders own 0.27% of the company's stock.
About Gilead Sciences
(
Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Featured Articles
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
